Nkarta selloff brings buying opportunity, says H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar views the post-earnings selloff in shares of Nkarta as a buying opportunity. The updated data for NKX101 for treatment of acute myeloid leukemia are on track for the first half of 2023, the analyst tells investors in a research note. The firm believes Nkarta is in a favorable position as the front-runner in the CAR-NK space, and believes current levels present a favorable entry point as expectations for AML data "appear low."